ClinicalTrials.gg
RecruitingNCT06447597Updated Aug 14, 2026

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

A Phase 2/3 interventional study of B007 and Placebo in Generalized Myasthenia Gravis, sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd. Recruiting at 18 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Shanghai Jiaolian Drug Research and Development Co., Ltd · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 88 studies in Myasthenia Gravis with a site in China — 48 open to participants now, 59 under way, 16 of them phase 3. Myasthenia Gravis · China.

Planned enrollment
20th of 67
104 · median 40
Started
2024
with 15 others
Phase 2/3
2 of 88
2 open now
Primary completion
2026-12
later than 20 of 58 live
Registered
45th of 88
by date

Among the 88 studies in Myasthenia Gravis with a site in China, this one is the 20th largest by planned enrollment of the 67 interventional ones that give a count, is one of 16 that started in 2024, is one of 2 in phase 2/3, reaches primary completion later than 20 of the 58 other live ones, and was the 45th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

48 of the 88 studies in Myasthenia Gravis with a site in China are open now. Recruiting first, the newest first:

42 more — sign in →

All 48 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Myasthenia Gravis with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of B007 in subjects with generalized myasthenia gravis.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Sign form;
  2. Subjects with generalized myasthenia gravis;
  3. Serum AchR(Acetylcholine receptor)-Ab or MUSK-Ab was positive during screening;
  4. MG-ADL ≥5 at screening and baseline;
  5. Before randomization, subjects received at least one gMG stable dose of SoC, and maintain a stable dose throughout the test;
  6. Subjects agree to use effective methods for contraception from signing the informed consent form to 1 year after the last dose. Female subjects considered fertile by the investigator must have negative serum pregnancy tests before the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with MGFA I and V type;
  2. Subjects usingprescribed drugs;
  3. Subjects with a prescribed disease or history of disease;
  4. The subjects has prescribed examination abnormalities that are assessed as unsuitable for participation in the study by the investigator;
  5. Known history of severe allergic reaction to humanized monoclonal antibodies, or known allergy to any component of B007;
  6. Subjects who received at the specified time before the first dose and are expected to receive the vaccine at the specified time after the last dose;
  7. Subjects who have received major surgery or participated in other clinical trials within the prescribed time before screening;
  8. Pregnant and lactating women;
  9. Fertile female subjects do not agree to use effective from signing the form to 1 years after the last dose.
  10. Sexually active male subjects who do not intend to use an effective contraceptive method during the trial period or within1 years after the last dose, or male subjects who plan to donate sperm during the trial or within 1 year after the last dose;
  11. A history of alcohol or drug abuse within the past 12 months;
  12. Other conditions deemed unsuitable for participation in this study by the researchers.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    B007

    Drug: B007

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugB007

    B007 high dose and low dose: Subcutaneous injection was administered on days 1 and 15

  • DrugPlacebo

    B007 matched Placebo Subcutaneous injection was administered on days 1 and 15

06

What researchers measure

Primary outcomes

  1. Proportion of subjects:MG-ADL(Myasthenia gravis-activities of daily living profile) decreased by ≥2

    Proportion of subjects:MG-ADL decreased by ≥2

    Time frame: Approximately 16 weeks

Secondary outcomes

  1. Proportion of subjects:subjects without SoC(Standard of Care) change and MG-ADL decreased by ≥2

    Proportion of subjects:subjects without SoC change and MG-ADL decreased by ≥2

    Time frame: Approximately 24 weeks

  2. Proportion of subjects:subjects without SoC change and QMG(Quantitative Myasthenia Gravis score) decreased by ≥3

    Proportion of subjects:subjects without SoC change and QMG decreased by ≥3

    Time frame: Approximately 24 weeks

  3. Changes in MGQoL15r (Myasthenia gravis quality of life15-item revised) from baseline.

    Changes in MGQoL15r from baseline.

    Time frame: Approximately 24 weeks

  4. Changes in MGC (Myasthenia gravis composite) from baseline.

    Changes in MGC from baseline

    Time frame: Approximately 24 weeks

  5. Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration

    Time frame: Approximately 1 years

07

Study locations

18 of 18 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2024
First posted
Jun 7, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06447597
Lead sponsor
Shanghai Jiaolian Drug Research and Development Co., Ltd
Responsible party
Sponsor
First posted
Jun 7, 2024
Start date
Jul 1, 2024
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 14, 2026

Study contacts

Jianying Xi
Contact
hsyybwc@163.com
0086-021-52888045
Huan Yang
Contact
xyyyllwyh@126.com
0086-0731-84327919

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: B007

Start the discussion